Cannabis Use Disorder Recovery Support Protocol

Cannabis Use Disorder (CUD) is characterized by problematic cannabis use leading to significant impairment or distress. Signs include using more than intended, difficulty cutting down, spending excessive time obtaining or using cannabis, cravings, continued use despite problems, and withdrawal symptoms when stopping. With increasing cannabis potency and legal availability, CUD has become more common. Withdrawal symptoms include irritability, anxiety, sleep problems, decreased appetite, restlessness, and physical discomfort - typically starting 1-3 days after stopping and peaking around 1 week.

CRITICAL: While cannabis is often perceived as non-addictive, about 9% of users develop CUD (higher with earlier onset or daily use). There are currently no FDA-approved medications for CUD, but evidence-based behavioral treatments are effective: Motivational Enhancement Therapy (MET), Cognitive Behavioral Therapy (CBT), and Contingency Management. If you want to quit, consider seeking help from an addiction specialist or treatment program. These supplements may support recovery but should complement, not replace, professional treatment.

* N-Acetyl Cysteine (NAC) has the strongest evidence for CUD. Clinical trials show it modulates glutamate (disrupted by chronic cannabis use) and can reduce cravings and cannabis use, particularly in younger users.

* Omega-3 Fatty Acids support brain health and may help with mood regulation during recovery.

* Magnesium helps with anxiety and sleep - common withdrawal symptoms.

* Vitamin D is often low in substance users and supports overall health and mood.

* Ashwagandha is an adaptogen that may help manage stress and anxiety during recovery.

* L-Theanine promotes calm without sedation, helpful for anxiety.

* Melatonin addresses sleep disturbances, which are very common during cannabis withdrawal and can last weeks.

* B Vitamins support nervous system function.

Expected timeline: Acute withdrawal symptoms typically peak around day 7 and improve over 2-4 weeks. Sleep problems may persist longer. Full neurological recovery may take months of abstinence.

Clinical Perspective

Cannabis Use Disorder (CUD): DSM-5 criteria - problematic use with ≥2 of 11 criteria within 12 months (larger amounts/longer than intended, desire/unsuccessful efforts to cut down, time spent obtaining/using/recovering, craving, failure to fulfill obligations, continued use despite social/interpersonal problems, activities given up, use in hazardous situations, continued despite physical/psychological problems, tolerance, withdrawal). Severity: mild (2-3), moderate (4-5), severe (≥6). Prevalence: ~9% of users develop CUD; higher with early onset, daily use, high-potency products.

CRITICAL: No FDA-approved medications for CUD. Evidence-based treatments: MET, CBT, Contingency Management. Medications studied: gabapentin, NAC, dronabinol, buspirone - none definitively proven. Withdrawal syndrome: irritability, anxiety, depression, sleep disturbance, decreased appetite, restlessness, physical symptoms. Onset day 1-3, peak day 7, duration 2-4 weeks (sleep issues longer). Co-occurring disorders common: anxiety, depression, other substance use. Supplements support but don't replace behavioral treatment.

* NAC (B-grade): Glutamate modulation; cystine-glutamate antiporter. Clinical trial: reduced use (PMID: 22840792). Adolescent trial: benefit in treatment-seeking youth (PMID: 28433712). 1200mg BID.

* Omega-3 Fatty Acids (C-grade): Brain health; anti-inflammatory. Review: substance use disorders (PMID: 23218897). 2-3g EPA+DHA daily.

* Magnesium (C-grade): Nervous system support. Systematic review: anxiety benefit (PMID: 28445426). 300-400mg daily.

* Vitamin D (C-grade): Often deficient in substance users. Review: substance use (PMID: 29698420). 2000-4000 IU daily.

* Ashwagandha (C-grade): Adaptogenic; cortisol modulation. Systematic review: anxiety reduction (PMID: 32021735). 300-600mg daily.

* L-Theanine (C-grade): GABA/glutamate modulation. Systematic review: anxiety/stress (PMID: 31412272). 200-400mg daily.

* Melatonin (C-grade): Sleep support. Review: substance use recovery (PMID: 23444785). 0.5-5mg at bedtime.

* B Vitamins (C-grade): Nervous system cofactors. Review: substance use (PMID: 23499998). B-complex daily.

Biomarker targets: Abstinence (urine drug screens), withdrawal symptom severity, sleep quality, mood/anxiety measures, quality of life.

Protocol notes: Withdrawal management: symptoms are uncomfortable but not medically dangerous. Sleep: most persistent symptom; sleep hygiene important; melatonin or trazodone sometimes used. Anxiety: distinguish from underlying anxiety disorder (may emerge/worsen when cannabis stopped). Depression: monitor closely; cannabis may have been masking depression. Exercise: very helpful for mood, sleep, cravings. Support groups: Marijuana Anonymous available. High-potency products (concentrates, dabs): may lead to more severe CUD. Synthetic cannabinoids (K2/Spice): different - more dangerous, unpredictable withdrawal. Co-use with tobacco: address both. Cognitive effects: may take weeks-months to fully recover; reassure patients. Adolescents: brain still developing; earlier onset = higher CUD risk. NAC: best evidence in adolescents/young adults who want to quit. Treatment engagement: motivational interviewing approach helpful - avoid confrontation. Relapse: common; part of recovery process.

View All Protocols